Clinical Trials

AIO is pleased to announce its participation in the following clinical trials: 

 

Trials Currently Enrolling: 

  • Investigator Driven, Observational Study
    6-month trial to assess the safety and efficacy of Macugen    ® (pegaptanib sodium injection) plus Pan-Retinal Laser Photocoagulation (PRP) combination therapy vs PRP alone in subjects with high-risk Proliferative Diabetic Retinopathy (PDR)   

  • Phase IV, Observational Study                                                       1-yr trial to assess the effect of intravitreal injections of  Macugen® administered every 6 weeks for 48 weeks on corneal endothelium for subjects with subfoveal neovascular Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME) or Retinal Vein Occlusion (RVO) 

  • Phase III, InvestigationalStudy                                                       1-yr trial to assess the safety and efficacy of intravitreal injections of  DE-109 for the treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the eye

Trials in follow-up: 

  • Device, Investigational Study                                                         2-yr trial to assess the safety and efficacy of the Cypass implant in lowering Intraocular Pressure (IOP) in subjects with glaucomatous eyes in conjunction with cataract surgery, as compared to cataract surgery alone

  • Phase III, Investigational Study                                                      2-yr trial to assess the efficacy and safety of monthly intravitreal injections of Ranibizumab compared with monthly sham injections for subjects with Clinicaly Significant Macular Edema with Central Involvement (CSME-CI) secondary to Diabetes Mellitus (Type I or Type II)

  • VEGF Trap-Eye Extention Study
    30-month trial to assess the long-term safety and tolerability of VEGF Trap-Eye in patients with neovascular AMD     

  • Phase III, Investigational Study                                                          2-yr trial to assess the efficacy and safety of monthly, or on an As-Needed Basis in subjects with Subfoveal Neovascular AMD Ranibizumab administered 

 

 

 

Picture 24.png

 

 

 

 

 

 

 

 

 

 

 

Research Mission Statement

Associates in Ophthalmology is dedicated to providing the highest quality of care while contributing to the global effort to alleviate diseases of the eye through teaching and research.  Serving as a world-class research and educational organization, we are dedicated to the preservation and restoration of vision.

The Research Institute Staff

  • Miguel Busquets, MD, FACS - Director
  • Stephen Logsdon - Director of Clinical Research
  • Gidget Pastorius, MA - Study Coordinator/Lab Technician
  • Rhonda Dahlstrom - VA Examiner/Coordinator
  • Joanna Stettmier, RN - Treatment Assistant
  • Melanie Hreha - Technician

Previous Trials:

The Research Institute of AIO has been involved with FDA trials since 2003.  They have included treatment for Cataracts, Conjunctivitis, Corneal Infiltrates, CME from BRVO/CRVO, ARMD, NPDR, and Glaucoma.